| NCT04495153 | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-10-13 | 2026-12 | 2024-12-31 |
| NCT03576612 | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas | COMPLETED | PHASE1 | 2018-02-27 | 2023-06-30 | 2023-06-30 |
| NCT03131037 | Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer | COMPLETED | PHASE1 | 2017-05-04 | 2023-09-20 | 2021-12-01 |
| NCT02768363 | Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | ACTIVE_NOT_RECRUITING | PHASE2 | 2016-05 | 2026-12 | 2024-11 |
| NCT02446093 | Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2015-10 | 2026-07 | 2025-12 |
| NCT01997190 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion | COMPLETED | PHASE1 | 2013-10 | 2018-02 | 2015-12 |
| NCT01436968 | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | ACTIVE_NOT_RECRUITING | PHASE3 | 2011-09 | 2030-12 | 2024-08 |
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | COMPLETED | PHASE1 | 2010-10 | 2021-06 | 2015-12 |
| NCT00638612 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) | COMPLETED | PHASE1 | 2008-08 | 2015-06 | 2013-05 |
| NCT00589875 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | COMPLETED | PHASE2 | 2007-03 | 2016-08 | 2015-12 |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | COMPLETED | PHASE1 | 2005-11 | 2011-01 | 2010-01 |